Ropinirole for the treatment of restless legs syndrome

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 407-419

  Kushida, Clete A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Periodic limb movements; Restless legs syndrome; RLS; Ropinirole

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; IRON; LEVODOPA; OPIATE; PLACEBO; ROPINIROLE;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG URINE LEVEL; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LEG MOVEMENT; MOOD; MOTOR DYSFUNCTION; NAUSEA; OPEN STUDY; PATHOLOGICAL GAMBLING; PERIODIC LIMB MOVEMENT; QUALITY OF LIFE; REBOUND; RESTLESS LEGS SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP PARAMETERS; SOMNOLENCE; UNITED STATES; VOMITING;

EID: 33847321178     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.407     Document Type: Article

References (89)

1. Abetz L, Arbuckle R, Allen RP, et al. 2005. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes, 3:79.
2. Adler CH, Hauser RA, Sethi K, et al. 2004. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology, 62:1405-7.
3. Allen RP, Barker PB, Wehrl F, et al. 2001. MRI measurement of brain iron in patients with restless legs syndrome. Neurology, 56:263-5.
4. Allen R, Becker PM, Bogan R, et al. 2004a. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep, 27:907-14.
5. Allen RP, Earley CJ. 2000. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med, 1:11-19.
6. Allen RP, Earley C. 2001. Validation of a diagnostic questionnaire for the restless legs syndrome (RLS). Neurology, 58:A4.
7. Allen RP, Grunstein R, Tidswell P, et al. 2004c. Alleviation of motor symptoms and consequent sleep benefits with ropinirole in RLS. Associated Professional Sleep Societies, Chicago, USA, June 5-10, 2004. Sleep, 27(abstract suppl):A295: 661.
8. Allen RP, Grunstein R, Tidswell P, et al. 2004d. Ropinirole in RLS: alleviation of motor symptoms and consequent sleep benefits. American Academy of Neurology, San Francisco, USA, April 24-May 1, 2004. Neurology, 62(Suppl 5):P01.079.
9. Allen R, Mistry P, Kelly M. 2004b. Ropinirole reduces periodic leg movements in sleep in patients with RLS. International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 13-17, 2004. Mov Disord, 19(Suppl 9):S430: P1261.
10. Allen RP, Picchietti D, Hening WA, et al. 2003. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med, 4:101-19.
11. Allen RP, Tidswell P, Ritchie S. 2005b. Clinical efficacy of ropinirole for RLS is unaffected by age-at-onset phenotype: pooled analysis of three clinical trials. American Academy of Neurology, Miami Beach, FL, USA, April 9-16, 2005. Neurology, 64(Suppl 1):A41-2.
12. Allen R, Trenkwalder C, Earl N, 2005a. Ropinirole treatment of RLS gives rapid improvement in clinician-rated global symptoms: results from an extensive clinical trial program. 19th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, CA, USA, Sept 25, 2005. Mov Disord, 20:1235-49. P1231 OMD.
13. American Academy of Sleep Medicine. 2005. International classification of sleep disorders, 2nd ed.: Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine.
14. Atkinson MJ, Allen RP, DuChane J, et al. 2004. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res, 13:679-93.
15. Bassetti C, Clavadetscher S, Gugger M, et al. 2002. Pergolide-associated sleep attacks' in a patient with restless legs syndrome. Sleep Med, 3:275-7.
16. Becker P, Ondo W, Weerd A, et al. 2004. An early onset of action in RLS: results from the ropinirole clinical trials program. Associated Professional Sleep Societies, Chicago, USA, June 5-10, 2004. Sleep, 27(abstract suppi):A294-5:659.
17. Bliwise DL, Freeman A, Ingram CD, et al. 2005. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med, 6:141-7.
18. Bogan R, Fry J, Schmidt M, et al. 2005a. An early onset of action: ropinirole treatment for moderate-to-severe RLS. European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005. Eur J Neurol, 12(Suppl 2):SC205.
19. Bogan RK, Fry JM, Schmidt MH, et al. 2006. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc, 81:17-27.
20. Bogan R, García-Borreguero D, Ball E. 2005b. Long-term improvements in sleep and quality of life: data from 52-week studies of ropinirole in RLS. European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005. Eur J Neurol, 12(Suppl 2):SC204.
21. Bonati MT, Ferini-Strambi L, Aridon P, et al. 2003. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain, 126:1485-92.
22. Chesson AL Jr, Wise M, Davila D, et al. 1999. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep, 22:961-8.
23. Connor JR, Boyer PJ, Menzies SL, et al. 2003. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 61:304-9.
24. Desautels A, Turecki G, Montplaisir J, et al. 2001. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet, 69:1266-70.
25. Dodd ML, Klos KJ, Bower JH, et al. 2005. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol, 62:1377-81.
26. Dreykluft T, Garcia-Borreguero D, Lee D. 2005. Long-term safety and efficacy of ropinirole in moderate-to-severe RLS: results of two 52-week, open-label studies. European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005. Eur J Neurol, 12(Suppl 2):P1244.
27. Driver-Dunckley E, Samanta J, Stacy M. 2003. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology, 61:422-3.
28. Earley CJ, Allen RP, Beard JL, et al. 2000a. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res, 62:623-8.
29. Earle CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology, 54:1698-700.
30. Eisensehr I, Wetter TC, Linke R, et al. 2001. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology, 57:1307-9.
31. Estivill E, de la Fuente V. 1999a. [The use of ropinirol ++ as a treatment for restless leg syndrome]. Rev Neurol, 28:962-3.
32. Estivill E, de la Fuente V. 1999b. [The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data]. Rev Neurol, 29:805-7.
33. Ferini-Strambi L, Montplaisir J, Dreykluft T. 2004. The evidence base for ropinirole in RLS: results from an extensive clinical trial programme. International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 13-17, 2004. Mov Disord, 19(Suppl 9):S424: P1243.
34. Frucht S, Rogers JD, Greene PE, et al. 1999. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology, 52:1908-10.
35. Galvez-Jimenez N, Khan T. 1999. Ropinirole and restless legs syndrome. Mov Disord, 14:890-2.
36. Garcia-Borreguero D, Bogan R, Ritchie S. 2005a. Ropinirole in RLS: determining the effective dose range. European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005. Eur J Neurol, 12(Suppl 2):P2200.
37. Garcia-Borreguero D, Bogan R, Ritchie S. 2005b. The effective dose of ropinirole in the treatment of patients with restless legs syndrome. 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LO, USA, March 5-8, 2005. Mov Disord, 20(Suppl 10):P218.
38. Garcia-Borreguero D, Lee D, Ball E. 2005c. Ropinirole is well tolerated and effective for the long-term treatment of RLS. American Academy of Neurology, Miami Beach, FL, USA, April 9-16, 2005. Neurology, 64(Suppl 1):A42: P01.046.
39. Haan J, Volc D, Montplaisir J. 2004. The long-term management of RLS with ropinirole: maintained efficacy over 36 weeks. International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 13-17, 2004. Mov Disord, 19(Suppl 9):S420: P1232.
40. Happe S, Sauter C, Klosch G, et al. 2003. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology, 48:82-6.
41. Hening W, Allen R, Earley C, et al. 1999. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep, 22:970-9.
42. Hening W, Walters AS, Allen RP. et al. 2004a. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med, 5:237-46.
43. Hening WA, Allen RP, Earley CJ, et al. 2004b. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep, 27:560-83.
44. Kageyama. T, Kabuto M, Nitta H, et al. 2000. Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci, 54:296-8.
45. Karrasch J, Haan J, Kruger AJ, et al. 2004. Maintained efficacy with ropinirole: results of a multinational 36-week study of patients with RLS. Associated Professional Sleep Societies, Chicago, USA, June 5-10, 2004. Sleep, 27(abstract suppl):A294: 658.
46. Kelly M, Mistry P. 2004. Ropinirole markedly reduces periodic leg movements during sleep (PLMS) in patients with RLS. European Federation of Neurological Societies, Paris; France, Sep 4-7, 2004. Eur J Neurol, 11(Suppl 2): 111: P 1291.
47. Kelly M, Mistry P. 2005. Tolerability of a forced-dose escalating regimen of ropinirole in patients with restless legs syndrome. 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA, USA, March 5-8, 2005. Mov Disord, 20(Suppl 10):P210.
48. Kuo TK, Kushida CA. 2003. Treatment efficacy of behavioral interventions for obstructive sleep apnea, restless legs syndrome, periodic leg movement disorder, and narcolepsy. In Perlis ML, Lichstein KL (eds). Treating sleep disorders: Principles and practice of behavioral sleep medicine. New Jersey: John Wiley & Sons, Inc. p 136-65.
49. Kushida CA, Allen RP, Atkinson MJ. 2004. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med, 5:485-8.
50. Kushida CA, Tolson JM. 2006. Ropinirole is an effective treatment for patients with restless legs syndrome (RLS) needing extended treatment coverage. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66:5(Suppl 2):P02.029:A082.
51. Lee DO, Becker P, Watson CB. 2006. Ropinirole improves symptoms in patients with moderate-to-severe primary restless legs syndrome (RLS) experiencing reduced daytime alertness. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66:5(Suppl2):P02.018:A079.
52. Lee DO, Earl N. 2006. Ropinirole effectively relieves restless legs syndrome (RLS) symptoms in patients with evening and nighttime symptoms. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66:5(Suppl2):P02.019:A080.
53. Littner MR, Kushida C, Anderson WM, et al. 2004. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep, 27:557-9.
54. Montagna P, Tidswell P, Yee B. 2004. The adverse-event profile of ropinirole in the treatment of RLS. International Congress of Parkinson's Disease and Movement Disorders, Rome, Italy, June 13-17, 2004. Mov Disord, 19(Suppl 9):S423: P1242.
55. Montplaisir J, Boucher S, Poirier G, et al. 1997. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord, 12:61-5.
56. Montplaisir J, Boucher S, Nicolas A, et al. 1998. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord, 13:324-9.
57. Montplaisir J, Karrasch J, Haan J, et al. 2004a. The impact of ropinirole treatment on RLS symptoms and health-related quality of life (HRQoL) in patients with RLS: results of a multinational 36-week study. Abstract presented at the Associated Professional Sleep Societies, Chicago, USA, June 5-10, 2004. Sleep, 27(abstract suppl):A293: 656.
58. Montplaisir J, Karrasch J, Haan J, et al. 2004b. The impact of ropinirole treatment on health-related quality of life in patients with RLS: results of a multinational 36-week study. American Academy of Neurology, San Francisco, USA, April 24-May 1, 2004. Neurology, 62(Suppl 5):P01.080.
59. Ondo W. 1999. Ropinirole for restless legs syndrome. Mov Disord, 14:138-40.
60. Ondo WG, Vuong KD, Wang Q. 2000. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology, 55:1404-6.
61. Ondo WG, Dat Vuong K, Khan H, et al. 2001. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology, 57:1392-6.
62. Pal S, Bhattacharya KF, Agapito C, et al. 2001. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm, 108:71-7.
63. Pellecchia MT, Vitale C, Sabatini M, et al. 2004. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol, 27:178-81.
64. Phillips B, Young T, Finn L, et al. 2000. Epidemiology of restless legs symptoms in adults. Arch Intern Med, 160:2137-41.
65. Plowman BK, Boggie DT, Morreale AP, et al. 2005. Sleep attacks in patients receiving dopamine-receptor agonists. Am J Health Syst Pharm, 62:537-40.
66. Ruottinen HM, Partinen M, Hublin C, et al. 2000. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology, 54:502-4.
67. Rye D, Allen R, Carson SW, et al. 2005. Ropinirole decreases bedtime periodic leg movements in patients with RLS: results of a 12-week US study. Associated Professional Sleep Societies, Denver, USA, June 18-23, 2005. Sleep, 28(Suppl):A270: 0802.
68. Rye DB, Bliwise DL, Dihenia B, et al. 2000. Daytime sleepiness in Parkinson's disease. J Sleep Research, 9:63-9.
69. Saletu B, Gruber G, Saletu M, et al. 2000a. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology, 41:181-9.
70. Saletu M, Anderer P, Saletu B, et al. 2000b. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology, 41:190-9.
71. Sethi K, Carson SW. 2005. Ropinirole improves RLS symptoms at starting dose: results from TREAT RLS US. 19th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, San Diego, CA, USA, Sept 25, 2005. Mov Disord, 20:1235-49. P1222 OMD.
72. Sethi KP, Hosford DA. 2006. Ropinirole provides symptom relief in patients with restless legs syndrome (RLS) regardless of family history: Combined subgroup analysis of three clinical trials. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66(Suppl 2):P02.023:A081.
73. Sevim S, Dogu O, Camdeviren H, et al. 2003. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology, 61:1562-9.
74. Silber MH, Ehrenberg BL, Allen RP, et al. 2004. An algorithm for the management of restless legs syndrome. Mayo Clin Proc, 79:916-22.
75. Stiasny-Kolster K, Magerl W, Oertel WH, et al. 2004. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain, 127:773-82.
76. Sun ER, Chen CA, Ho G, et al. 1998. Iron and the restless legs syndrome. Sleep, 21:371-7.
77. Tan EK, Seah A, See SJ, et al. 2001. Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord, 16:577-9.
78. The Atlas Task Force. 1993. Recording and scoring leg movements. Sleep, 16:748-59.
79. Thomas KM, Becker P, Watson CB. 2006. Ropinirole relieves mood symptoms in patients with moderate-to-severe primary restless legs syndrome (RLS). American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66(Suppl2):P02.024:A081.
80. Thomason Healthcare. 2005. Requip [online]. Accessed 7 March 2006. URL: http://www.pdr.net.
81. Tidswell P, Garcia-Borreguero D, Trenkwalder C. 2004. Ropinirole in RLS: efficacy results from an extensive clinical trial programme. European Federation of Neurological Societies, Paris, France, Sep 4-7, 2004. Eur J Neurol, 11(Suppl 2):115: P1302.
82. Tompson D, Della Pasqua O. 2004. A single-blind, placebo-controlled, forced-titration study of ropinirole in RLS: pharmacokinetic-pharmacodynamic relationships. Associated Professional Sleep Societies, Chicago, USA, June 5-10, 2004. Sleep, 27(abstract suppl):A298-9: 668.
83. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. 2004. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry, 75:92-7.
84. Turjanski N, Lees AJ, Brooks DJ. 1999. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology, 52:932-7.
85. Walters AS, LeBrocq C, Dhar A, et al. 2003. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med, 4:121-32.
86. Walters AS, Ondo WG, Dreykluft T, et al. 2004. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord, 19:1414-23.
87. Winkelmann J, Lichtner P, Putz B, et al. 2006. Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord, 21:28-33.
88. Ziman RB, Earl NL, Kushida CA, et al. 2006a. Ropinirole is an effective treatment for restless legs syndrome (RLS) in patients who have failed other therapies. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66(Suppl 2):P02.026:A081.
89. Ziman RB, Watson CB, Bogan RK. 2006b. Onset of symptom improvement after 2 nights in patients with restless legs syndrome (RLS) treated with ropinirole. American Academy of Neurology, San Diego, CA, USA, April 1-8, 2006. Neurology, 66(Suppl 2):P02.028:A082.